TRISH to study spaceflight effects on genome and nervous system on Axiom Space's Ax-3 Mission
The Translational Research Institute for Space Health (TRISH) will conduct a suite of human health and performance research projects during Axiom Space’s upcoming Axiom Mission 3 (Ax-3) to the International Space Station (ISS), scheduled to launch in 2024.
The selected research projects are designed to enhance understanding of the human experience in space and inform the development of high-impact scientific and technological solutions to help humans thrive on future space missions. Each project is part of TRISH’s commercial spaceflight health research program, Enhancing eXploration Platforms and Analog Definition (EXPAND).
The projects are led by researchers from across the nation who will investigate key space health topics, including space motion sickness, sleep disturbance, genome alterations, changes to cognitive function and eye and brain health.
TRISH-Supported Ax-3 Research Projects
TRISH established the first-of-its-kind research platform to study human health and performance in private spaceflight participants in 2021. Working with commercial spaceflight providers and their passengers, TRISH’s EXPAND Program collects pre-, in-, and post-flight health data from multiple commercial space flights and data is housed it in a centralized research database.
Soon, TRISH will begin sharing the data and biosamples collected from these commercial space missions to further space health research and, in turn, further human space exploration.